Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis
- PMID: 27785526
- DOI: 10.1007/s00059-016-4470-0
Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis
Abstract
A comprehensive meta-analysis was performed to investigate whether the combination of high-/low-dose of aspirin and various intensities of warfarin (W) offer greater benefit than aspirin (ASA) alone. A total of 14 randomized clinical trials (RCTs) having 26,916 patients with acute coronary syndrome (ACS) met inclusion criteria. The efficacy and safety of all outcomes which included myocardial infarction (MI), all-cause death, stroke, and bleeding were calculated. The overall outcomes analysis showed there was no significant difference in the risk of MI (relative ratio [RR] 0.959, 95 % confidence interval [CI] 0.78-1.04, P = 0.308), stroke (RR 0.789, 95 % CI 0.57-1.09, P = 0.145), and all-cause death (RR 1.007, 95 % CI 0.93-1.09, P = 0.87) between the combination group and ASA group. The subgroup analysis suggested that ASA (≤100 mg/day) plus W (mean international normalized ratio [INR] 2.0-3.0) decreased the risk rate of stroke (RR 0.660, 95 % CI 0.50-0.87, P = 0.003). There was a lower risk of MI (RR 0.605, 95 % CI 0.47-0.77, P < 0.0001) as well as stroke (RR 0.594, 95 % CI 0.45-0.79, P < 0.0001) between W (INR 2.0-3.0) combined with ASA (mean dose ≥100 mg/day) and ASA. However, the risk of major bleeding (RR 1.738, 95 % CI 1.45-2.08, P < 0.0001) and minor bleeding (RR 2.767, 95 % CI 2.12-3.61, P < 0.0001) was almost doubled in the combined groups. Compared with ASA, high-dose aspirin with moderate-intensity warfarin (INR 2.0-3.0) may better reduce the risk of MI and stroke but confer an increased risk of bleeding.
Keywords: All-cause death; Anticoagulants; Bleeding; Myocardial infarction; Stroke.
Similar articles
-
Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.Circulation. 1998 Sep 15;98(11):1064-70. doi: 10.1161/01.cir.98.11.1064. Circulation. 1998. PMID: 9736592 Clinical Trial.
-
Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment. A meta-analysis.Herz. 2015 Dec;40(8):1070-83. doi: 10.1007/s00059-015-4325-0. Epub 2015 Jul 2. Herz. 2015. PMID: 26135462 Review.
-
Should aspirin be continued in patients started on warfarin?J Gen Intern Med. 2004 Aug;19(8):879-86. doi: 10.1111/j.1525-1497.2004.30419.x. J Gen Intern Med. 2004. PMID: 15242475 Free PMC article. Review.
-
Efficacy and Safety of Triple Therapy and Dual Therapy With Direct Oral Anticoagulants Compared to Warfarin.Int Heart J. 2017 Aug 3;58(4):570-576. doi: 10.1536/ihj.16-381. Epub 2017 Jul 13. Int Heart J. 2017. PMID: 28701676
-
Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies.Catheter Cardiovasc Interv. 2016 Jul;88(1):E12-22. doi: 10.1002/ccd.26234. Epub 2015 Sep 10. Catheter Cardiovasc Interv. 2016. PMID: 26354765 Review.
Cited by
-
Outcomes of Different Regimens of Rivaroxaban and Aspirin in Cardiovascular Diseases: A Network Meta-Analysis.J Clin Med. 2025 May 14;14(10):3437. doi: 10.3390/jcm14103437. J Clin Med. 2025. PMID: 40429430 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous